PARIS–(BUSINESS WIRE)–Regulatory News: Advicenne (Euronext Growth Paris – FR0013296746 – ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that it has received the remaining tranche of the financing, with a net amount of €1.0 million, under the bond financing agreement entered into with a fund managed by L1 Capital1. Following this additional funding, Advicenne has strengthene